Total revenue of $101 million, compared to $6 million in Q3 2021 Four program starts in the quarter, bringing cumulative total to 92, up 33% from Q3 2021 Net earnings of $0.09 per share on a basic and $0.08 on a diluted basis, compared to a net loss
Reinforcing GLC’s Commitment to Sustainable Processing in Pharmaceutical Chemistry OAKVILLE, Ontario--(BUSINESS WIRE)--GL CHEMTEC (“GLC”), a specialist in advanced chemistry R&D and scale-up services to support Active Pharmaceutical Ingredient
BURLINGTON, Ontario--(BUSINESS WIRE)--Anaergia Inc. (“Anaergia” or the “Company”) (TSX: ANRG) will release financial results for the third quarter of 2022 before market open on Thursday, November 10, 2022. Conference Call and Webcast Details A c
DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass.--(BUSINESS WIRE)--$IMV #DeliveryPlatform--IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX® platform to treat solid and hemato
Mucci Farms Boemberry Facility to Use Sollum’s Dynamic LED Grow Light Solution to Cultivate a Demanding Crop, Strawberries MONTREAL--(BUSINESS WIRE)--#Agriculture--Mucci Farms is looking to hone their expertise in strawberry cultivation by conducting o
Preclinical data support the clinical potential of Turnstone’s next-generation Selected TIL therapy to improve TIL efficacy against solid tumor malignancies Presentations highlight novel method to select the most potent tumor-reactive T-cells (Selecte
SASKATOON, Saskatchewan--(BUSINESS WIRE)--Nutrien Ltd. (TSX and NYSE: NTR) today announced the pricing of US$500 million aggregate principal amount of 5.900 percent senior notes due November 7, 2024 and US$500 million aggregate principal amount of 5.950 p
Official US rollout kicks off with coveted award from Cosmopolitan Magazine and new $99/month* patient financing options BRISBANE, Calif.--(BUSINESS WIRE)--Cutera, Inc. (Nasdaq: CUTR) ("Cutera" or the "Company"), a leading provider of aesthetic and derma
BOSTON--(BUSINESS WIRE)--Cerveau Technologies, Inc. today announced a license agreement with LEXEO Therapeutics, Inc. (LEXEO), which will enable LEXEO to use Cerveau’s [F-18]MK-6240, an investigational imaging agent, in Positron Emission Tomography (PET
VANCOUVER, British Columbia--(BUSINESS WIRE)--$ABCL--AbCellera (Nasdaq: ABCL) today announced that executives from the Company will present at the following investor conferences: Credit Suisse 31st Annual Healthcare Conference on Wednesday, November 9,
Sign up for one of BAM's newsletter to learn more about bioscience, happenings in Manitoba's bioeconomy, industry conferences, and BAM training events.